As of now, HANDAYUAN has been approved for the treatment of rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis and uveitis.
Autoimmune diseases are a group of diseases caused by the body's immune system attacking its own organs or tissues[1]. It is estimated that approximately 7.6%-9.4% of the global population suffers from various types of autoimmune diseases[2]. Currently, autoimmune diseases are difficult to cure, and once it occurs, most patients need long-term to lifelong medication. Some autoimmune diseases are particularly dangerous and severely affect the quality of life of patients, posing a threat to their lives and causing significant burden. Tumor necrosis factor- (TNF-) is one of the major cytokines that induce inflammation and other immune responses. It plays a key role in the pathogenesis of a variety of autoimmune diseases[3]. It has been proven that many autoimmune diseases such as rheumatoid arthritis, psoriasis and ankylosing spondylitis are closely related to TNF-. Adalimumab, a humanized anti-TNF- monoclonal antibody, can specifically bind to TNF- and block its interaction with TNF receptors p55 and p75, thereby effectively inhibiting the activity of TNF- and providing effective and long-lasting control of a variety of autoimmune diseases. With its good efficacy and safety in the treatment of autoimmune diseases, adalimumab has quickly replaced glucocorticoids and nonsteroidal anti-inflammatory drugs as one of prime choices in clinical practice. It has received recommendations from many global authoritative clinical treatment guidelines for autoimmune diseases, including the
HANDAYUAN is a monoclonal antibody biosimilar developed by Henlius in accordance with the Technical Guidelines for R&D and Evaluation of Biosimilars (Trial) and is also Henlius' first product approved for the treatment of autoimmune diseases. It received support from the
Currently, the commercialization of HANDAYUAN in
Looking forward, Henlius will adhere to the principle of patient centricity and take innovation as the driving force to explore and provide patients with more high-quality and affordable biological medicines and maximize the benefits for Chinese patients with autoimmune diseases.
Contact:
Tel: 021-33395800
(C) 2024 Electronic News Publishing, source